Diabetes, aging, and their tissue complications

Journal of Clinical Investigation

Volumn 124, Issue 5, 2014, Pages 1887-1888

  Bucala, Rick ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT;

AGING; ARTICLE; BLOOD VESSEL REACTIVITY; CARDIOVASCULAR FUNCTION; DIABETES MELLITUS; DIABETIC NEPHROPATHY; GLYCATION; HYPERGLYCEMIA; PRIORITY JOURNAL; PROTEIN CROSS LINKING; PROTEIN DEGRADATION; PROTEIN GLYCOSYLATION; PROTEIN PROCESSING; TISSUE INJURY; TRANSLATIONAL RESEARCH;

AGING; DIABETES MELLITUS; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; HYPERGLYCEMIA; NITRIC OXIDE;

EID: 84899763405     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI75224     Document Type: Article

References (15)

1. Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci U S A. 1987; 84(24):9265-9269.
2. Bucala R, Tracey KJ, Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest. 1991;87(2):432-438.
3. Hogan M, Cerami A, Bucala R. Advanced glycosylation endproducts block the antiproliferative effect of nitric oxide. Role in the vascular and renal complications of diabetes mellitus. J Clin Invest. 1992; 90(3):1110-1115.
4. Lee AT, Plump A, DeSimone C, Cerami A, Bucala R. A role for DNA mutations in diabetes-associated teratogenesis in transgenic embryos. Diabetes. 1995;44(1):20-24.
5. Bucala R, Makita Z, Koschinsky T, Cerami A, Vlassara H. Lipid advanced glycosylation: pathway for lipid oxidation in vivo. Proc Natl Acad Sci U S A. 1993;90(14):6434-6438.
6. Smith MA, et al. Advanced Maillard reaction end products are associated with Alzheimer disease pathology. Proc Natl Acad Sci U S A. 1994; 91(12):5710-5714.
7. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001; 414(6865):813-820.
8. Cerami C, et al. Tobacco smoke is a source of toxic reactive glycation products. Proc Natl Acad Sci U S A. 1997;94(25):13915-13920.
9. Koschinsky T, et al. Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci U S A. 1997;94(12):6474-6479.
10. Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science. 1986; 232(4758):1629-1632.
11. Vasan S, et al. An agent cleaving glucose-derived protein crosslinks in vitro and in vivo. Nature. 1996; 382(6588):275-278.
12. Engelen L, Stehouwer CD, Schalkwijk CG. Current therapeutic interventions in the glycation pathway: evidence from clinical studies. Diabetes Obes Metab. 2013;15(8):677-689.
13. Hammes HP, et al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med. 2003; 9(3):294-299.
14. Wang T, Kartika R, Spiegel DA. Exploring posttranslational arginine modification using chemically synthesized methylglyoxal hydroimidazolones. J Am Chem Soc. 2012;134(21):8958-8967.
15. Sell DR, Monnier VM. Molecular basis of arterial stiffening: role of glycation - a mini-review. Gerontology. 2012;58(3):227-237.